YMYoshihiro Morikawa

Yoshihiro Morikawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshihiro Morikawa has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Tadasuke Komori

    Department of Anatomy & Neurobiology, Wakayama Medical University, Wakayama, Japan

    11 shared publications
  • Emiko Senba

    From the Department of Anatomy and Neurobiology, Wakayama Medical University, Wakayama 641-8509, Japan and

    10 shared publications
  • Tomoko Hisaoka

    Department of Anatomy and Neurobiology, Wakayama Medical University, 811-1, Kimiidera, Wakayama, Wakayama 641-8509, Japan

    7 shared publications
  • Toshio Kitamura

    Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe, 6-3-7 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan; Molecular Pharmacology of Malignant Diseases, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

    7 shared publications
  • Atsushi Miyajima

    Laboratory of Cell Growth and Differentiation, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan

    6 shared publications
  • E. Senba

    4 shared publications

Latest Publications

  • Breakdown of blood–brain barrier, astrocytic endfeet swelling, and abnormal behaviors by blockade of TROY signaling in TROY-Fc transgenic mice

    by Tadasuke Komori, Tomoko Hisaoka, Emi Kuriyama, Mizuki Kajimoto, Naoyuki Nakao, Toshio Kitamura, Yoshihiro Morikawa


  • Open Access

    Suppression of renal crystal formation, inflammation, and fibrosis by blocking oncostatin M receptor β signaling

    by Ryusuke Deguchi, Tadasuke Komori, Shimpei Yamashita, Tomoko Hisaoka, Mizuki Kajimoto, Yasuo Kohjimoto, Isao Hara, Yoshihiro Morikawa

    Oncostatin M (OSM) has pleiotropic effects on various inflammatory diseases, including kidney stone disease. The prevalence of kidney stones has increased worldwide, despite recent therapeutic advances, due to its high recurrence rate, suggesting the importance of prevention of repeated recurrence in the treatment of kidney stone disease. Using a mouse model of renal crystal formation, we investigated the preventive effects of blockade of OSM receptor β (OSMRβ) signaling on the development of kidney stone disease by treatment with a monoclonal anti-OSMRβ antibody that we generated. The anti-OSMRβ antibody abrogated OSM-induced phosphorylation of STAT3 and expression of crystal-binding molecules (Opn, Anxa1, Anxa2) and inflammation/fibrosis-associated molecules (Tnfa, Tgfb, Col1a2) in renal tubular epithelial cells and fibroblasts. In glyoxylate-injected mice, a mouse model of renal crystal formation, there was significant suppression of crystal deposits and expression of crystal-binding molecules (Opn, Anxa1, Anxa2), a tubular injury marker (Kim-1), and inflammation/fibrosis-associated molecules (Tnfa, Il1b, Mcp-1, Tgfb, Col1a2) in the kidneys of the anti-OSMRβ antibody-treated mice, compared with those in vehicle- or isotype control antibody-treated mice. In addition, treatment with the anti-OSMRβ antibody significantly decreased infiltrating macrophages and fibrosis in the kidneys. These findings suggest that anti-OSMRβ antibody-treatment may be effective in preventing kidney stone disease.


  • Blockade of OSMRβ signaling ameliorates skin lesions in a mouse model of human atopic dermatitis

    by Tadasuke Komori, Tomoko Hisaoka, Ayumi Kotaki, Miki Iwamoto, Atsushi Miyajima, Eiji Esashi, Yoshihiro Morikawa

    Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by severe pruritus and eczematous skin lesions. Although IL‐31, a type 2 helper T (Th2)‐derived cytokine, is important to the development of pruritus and skin lesions in AD, the blockade of IL‐31 signaling does not improve the skin lesions in AD. Oncostatin M (OSM), a member of IL‐6 family of cytokines, plays important roles in the regulation of various inflammatory responses through OSM receptor β subunit (OSMRβ), a common receptor subunit for OSM and IL‐31. However, the effects of OSM on the pathogenesis of AD remain to be elucidated. When AD model mice were treated with OSM, skin lesions were exacerbated and IL‐4 production was increased in the lymph nodes. Next, we investigated the effects of the monoclonal antibody (mAb) against OSMRβ on the pathogenesis of AD. Treatment with the anti‐OSMRβ mAb (7D2) reduced skin severity score in AD model mice. In addition to skin lesions, scratching behavior was decreased by 7D2 mAb with the reduction in the number of OSMRβ‐positive neurons in the dorsal root ganglia of AD model mice. 7D2 mAb also reduced the serum concentration of IL‐4, IL‐13, and IgE as well as the gene expressions of IL‐4 and IL‐13 in the lymph nodes of AD model mice. Blockade of both IL‐31 and OSM signaling is suggested to suppress both pruritus and Th2 responses, resulting in the improvement of skin lesions in AD. The anti‐OSMRβ mAb may be a new therapeutic candidate for the treatment of AD.


  • Open Access

    Essential roles of oncostatin M receptor β signaling in renal crystal formation in mice

    by Shimpei Yamashita, Tadasuke Komori, Yasuo Kohjimoto, Atsushi Miyajima, Isao Hara, Yoshihiro Morikawa

    Oncostatin M (OSM), a member of the IL-6 family of cytokines, has important roles in renal diseases. The relationship between OSM and kidney stone disease, however, remains unclear. To investigate the roles of OSM in the development of kidney stone disease, we generated a mouse model of renal crystal formation using OSM receptor β (OSMRβ)-deficient mice (OSMRβ−/−mice). There were fewer renal crystal deposits in OSMRβ−/−mice than in wild-type (WT) mice. Crystal-binding molecules (osteopontin, annexin A1, and annexin A2), inflammatory cytokines (TNF-α and IL-1β), and fibrosis markers (TGF-β, collagen 1a2, and α-smooth muscle actin) were also decreased in the kidneys of OSMRβ−/−mice compared with those in WT mice. Immunofluorescence staining showed that OSMRβ was expressed in renal tubular epithelial cells (RTECs) and renal fibroblasts in the model of renal crystal formation. In the cultured RTECs and renal fibroblasts, OSM directly induced the expression of crystal-binding molecules and fibrosis markers. Expressions of inflammatory cytokines were increased by stimulation with OSM in cultured renal fibroblasts. OSM may promote the formation of renal crystal deposits by directly acting on RTECs and renal fibroblasts to produce crystal-binding molecules and inflammatory cytokines.


  • Open Access

    Abnormal behaviours relevant to neurodevelopmental disorders in Kirrel3-knockout mice

    by Tomoko Hisaoka, Tadasuke Komori, Toshio Kitamura, Yoshihiro Morikawa

    In the nervous system, Kirrel3 is involved in neuronal migration, axonal fasciculation, and synapse formation. Recently, genetic links have been reported between mutations in the KIRREL3 gene and increased risk of neurodevelopmental disorders, including autism spectrum disorder (ASD) and intellectual disability. To elucidate the causal relationship between KIRREL3 deficiency and behavioural abnormalities relevant to neurodevelopmental disorders, we generated global Kirrel3-knockout (Kirrel3−/−) mice and investigated the detailed behavioural phenotypes. In the three-chambered social approach test, Kirrel3−/−mice displayed a significant preference for a mouse over a non-social object but no significant preference for a stranger mouse over a familiar mouse. Ultrasonic communications, including pup-to-mother calls, male-female courtship vocalisation and resident responses to intruder, were significantly impaired in Kirrel3−/−mice. Significant increases in locomotor activity and repetitive rearing were also observed in Kirrel3−/−mice. Furthermore, the performance of Kirrel3−/−mice in the rotarod test was significantly better than that of wild-type mice. In the acoustic startle test, Kirrel3−/−mice were significantly hypersensitive to acoustic stimuli. Anxiety-related behaviours and spatial or fear memory acquisition were normal in Kirrel3−/−mice. These findings suggest that Kirrel3−/−mice exhibit autistic-like behaviours, including social and communicative deficits, repetitive behaviours, and sensory abnormalities, as well as hyperactivity.


  • Open Access

    Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice

    by Tadasuke Komori, Minoru Tanaka, Hiroto Furuta, Takashi Akamizu, Atsushi Miyajima, Yoshihiro Morikawa

    Obesity and insulin resistance are closely associated with adipose tissue dysfunction caused by the abnormal recruitment of inflammatory cells, including macrophages. Oncostatin M (OSM), a member of the IL-6 family of cytokines, plays important roles in a variety of biological functions including the regulation of inflammatory responses. In previous reports, we have demonstrated that mice deficient in the OSM receptor β subunit show obesity, adipose tissue inflammation, insulin resistance and hepatic steatosis, all of which are exacerbated by feeding the mice a high-fat diet. These results prompted us to test the therapeutic effects of OSM on obesity-induced metabolic disorders using mouse models of obesity. In diet-induced obese and ob/ob mice, metabolic variables were assessed physiologically, histologically and biochemically after the intraperitoneal injection of recombinant mouse OSM twice a day for 1 week. Treatment with OSM improved obesity, adipose tissue inflammation, insulin resistance and hepatic steatosis in both mouse models. Although OSM reduced food intake, such therapeutic effects of OSM were observed even under pair-feeding conditions. Functionally, OSM directly changed the phenotype of adipose tissue macrophages from M1 type (inflammatory) to M2 type (anti-inflammatory). In the liver, OSM suppressed the expression of genes related to fatty acid synthesis and increased the expression of genes related to fatty acid oxidation. Furthermore, OSM decreased lipid absorption and increased the expression of active glucagon-like peptide-1 in the intestine. We showed that OSM is a novel candidate to act as a powerful therapeutic agent for the treatment of obesity-induced metabolic disorders.


  • Open Access

    Deficiency of Oncostatin M Receptor β (OSMRβ) Exacerbates High-fat Diet-induced Obesity and Related Metabolic Disorders in Mice

    by Tadasuke Komori, Minoru Tanaka, Emiko Senba, Atsushi Miyajima, Yoshihiro Morikawa


  • Open Access

    Lack of Oncostatin M Receptor β Leads to Adipose Tissue Inflammation and Insulin Resistance by Switching Macrophage Phenotype

    by Tadasuke Komori, Minoru Tanaka, Emiko Senba, Atsushi Miyajima, Yoshihiro Morikawa